Rather, we propose host-targeting compounds like Vps34-IN-1 as complementary interventions that address key limitations in current control strategies—particularly in scenarios involving subclinical infections, delayed onset of vaccine-induced protection, or inadequate immunization coverage in the field—by offering a targeted means to suppress viral transmission. This evidence concerns the gene PIK3C3 and infection.